- Product Details
Keywords
- 935881-37-1
- AR-42
- good quality
Quick Details
- ProName: Newblue CHEM---AR-42
- CasNo: 935881-37-1
- Molecular Formula: C18H20N2O3
- Appearance: Colorless to light yellow liquid
- Application: Water treatment
- DeliveryTime: depends on yr quantity
- PackAge: 20kg/drum, 200kg/drum or 1000kg/IBC Dr...
- Port: china mian port
- ProductionCapacity: 10 Metric Ton/Month
- Purity: 98
- Storage: Room temperature
- Transportation: By sea , by air or express
- LimitNum: 1 Kilogram
- Grade: Industrial Grade,Electron Grade
- Purity: 98% Min
Superiority
Our company was built in 2009 with an ISO certificate.In the past 5 years, we have grown up as a famous fine chemicals supplier in China and we had established stable business relationships with Samsung,LG,Merck,Thermo Fisher Scientific and so on.Our main business covers the fields below:
1.Noble Metal Catalysts (Pt.Pd...)
2.Organic Phosphine Ligands (Tert-butyl-phosphine.Cyclohexyl-phosphine...)
3.OLED intermediates (Fluorene,Carbazole,Boric acid...)
4.Customs Synthesis
Our advantage:
1. Higest quality and good package
2.Fast delivery
3.Better payment term
4.Fast response to customer within 6 hours
5.Good business credit in Europe ,US ,Japan ,Korea
Anyway ,if you need any chemicals from China ,Henan Newblue can help you
Details
AR-42 Basic information |
Product Name: | AR-42 |
Synonyms: | AR-42;(S)-HDAC-42,AR-42;(S)-(+)-N-Hydroxy-4-(3-methyl-2-phenyl-butyrylamino)benzamide;(S)-HDAC 42;AR-42 (HDAC-42);HDAC-42;OSU-HDAC42;AR-42 (OSU-HDAC42) |
CAS: | 935881-37-1 |
MF: | C18H20N2O3 |
MW: | 312.363 |
EINECS: | -0 |
Product Categories: | Inhibitor;Inhibitors |
Mol File: | 935881-37-1.mol |
|
AR-42 Chemical Properties |
density | 1.223 |
Safety Information |
AR-42 Usage And Synthesis |
Usage | AR-42 is a broad spectrum deacetylase inhibitor of both histone and non-histone proteins, which has demonstrated greater potency and activity in solid tumors and hematological malignancies. AR-42 is k nown utilized as a novel, oral cancer therapy currently in early clinical development. |